Kayla Yates, PA
Physician Assistant · Bristol, TNNPI 1215547237
Payments from drug & device makers
Across 351 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$792
- Lilly USA, LLC$399
- Amgen$391
- AstraZeneca$362
- Esperion Therapeutics, Inc.$347
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,559100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 63 | $1,022 |
| AbbVie | 61 | $792 |
| Lilly USA, LLC | 22 | $399 |
| Amgen | 33 | $391 |
| AstraZeneca | 24 | $362 |
| Esperion Therapeutics, Inc. | 19 | $347 |
| GSK | 18 | $302 |
| Novartis | 13 | $232 |
| Exact Sciences | 9 | $184 |
| Johnson & Johnson | 10 | $159 |
| Pfizer | 8 | $140 |
| Merck | 9 | $134 |
| Bayer | 7 | $120 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $114 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $104 |
| Amarin Pharma, Inc. | 6 | $101 |
| Phathom Pharmaceuticals, Inc. | 3 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Sumitomo Pharma America, Inc. | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Boehringer Ingelheim | 3 | $38 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Mylan Specialty L.p. | 1 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $27 |
| Dexcom, Inc. | 2 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Inogen, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $21 |
| Corium, LLC | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $13 |
How this compares
$5,566 in reported general payments places this provider in the 90th percentile of 2,404 physician assistant providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 33 | $47,525 |
| OzempicSemaglutide | 29 | $41,322 |
| EliquisApixaban | 63 | $39,008 |
| JardianceEmpagliflozin | 39 | $35,671 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $29,115 |
| XareltoRivaroxaban | 32 | $28,502 |
| JanuviaSitagliptin Phosphate | 14 | $23,761 |
| Nurtec OdtRimegepant Sulfate | 11 | $20,350 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,667 |
| TrulicityDulaglutide | 14 | $13,911 |
| RybelsusSemaglutide | 13 | $13,281 |
| TradjentaLinagliptin | 22 | $13,199 |
| TrintellixVortioxetine Hydrobromide | 22 | $11,214 |
| EntrestoSacubitril/Valsartan | 15 | $10,419 |
| Repatha SureclickEvolocumab | 16 | $9,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $140 | $59,35874 claims |
| AbbVieVraylar, Linzess, Synthroid | $792 | $55,66068 claims |
| Novo NordiskOzempic, Rybelsus | $1,022 | $54,60342 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $302 | $51,27084 claims |
| Boehringer IngelheimJardiance, Tradjenta | $38 | $48,86961 claims |
| Johnson & JohnsonXarelto | $159 | $28,50232 claims |
| MerckJanuvia | $134 | $23,76114 claims |
| Lilly USA, LLCTrulicity | $399 | $13,91114 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $104 | $11,21422 claims |
| NovartisEntresto | $232 | $10,41915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,404 physician assistant providers in Tennessee.
Other physician assistant in Bristol
- Lindsey NixKnoxville$576K
- Anna KerseySavannah$399K
- Jason HenryNashville$329K
- Brie ChandlerNashville$317K
- Loree EasleyBartlett$209K
- Katherine RunyanKnoxville$156K
- John KramerNashville$125K
- Robert LaughertyAlcoa$122K
- Elisabeth BennettNashville$109K
- Whitney GatewoodMemphis$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.